Medical device company CurvaFix has raised $39m in Series C financing to expand the treatment for patients with Fragility Fractures of the Pelvis (FFP) across the US.
Through the nationwide launch of the CurvaFix IM Implant, the company aims to fundamentally transform the care provided to these patients.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The financing round was led by MVM Partners and included participation from Sectoral Asset Management, along with other existing investors.
CurvaFix already secured 510(k) clearance from the US Food and Drug Administration for its CurvaFix IM Implant.
CurvaFix is mainly focused on the development of implantable products for repairing fractures in curved bones.
MVM partner Eric Fritz said: “CurvaFix’s ability to benefit patients, physicians and health systems while simultaneously addressing the undertreated FFP segment, makes CurvaFix a rare asset in the crowded world of orthopaedics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are thrilled to be involved and look forward to supporting the company’s next phase of growth.”
Furthermore, CurvaFix has appointed Mark Foster as the company’s new CEO. He succeeded founder and current CEO Steve Dimmer, who will serve as strategic adviser.
Foster has experience in the medical device, pharmaceutical and healthcare industries, and is the former president and CEO of Trice Medical.
Foster said: “I have had the opportunity to observe the successful implementation and adoption of CurvaFix IM Implants in the orthopaedic pelvic fracture fixation market, for which Steve has played a pivotal role in taking the company to this point.
“I am looking forward to leading the CurvaFix team in scaling CurvaFix’s technology to benefit many more patients, physicians and payers.”
